Associate companies and HudsonAlpha win multiple Alabama Launchpad awards
HudsonAlpha associate company GeneCapture took home the $100,000 prize at the first Alabama Launchpad Alumni competition in May. The event brought together Alabama Launchpad winners from the past ten years and gave them the opportunity to pitch to a panel of judges.
“We are thrilled to have won the prize and the recognition for GeneCapture, HudsonAlpha and UAH. Alabama Launchpad helped us get started in the early days and now winning the Alumni competition is helping us enter a new phase where we are validating our prototype with actual human samples as we develop our rapid infection detection system,” said Peggy Sammon, CEO.
In June, the Economic Development Partnership of Alabama (EDPA) announced HudsonAlpha and associate companies iCubate and CFDRC winners of the Alabama Innovation Awards. EDPA, through its Alabama Launchpad program, recognizes innovation and the vital role entrepreneurs, startups and innovators contribute to Alabama’s economy and new job growth. HudsonAlpha and iCubate won the award for Outstanding Public-Private Partnership for Innovation. CFDRC won the award for Corporate Innovator of the Year for a large company.
HudsonAlpha, iCubate and CFDRC will be honored at the 6th Annual Alabama Innovation and Entrepreneurship Conference in Birmingham on August, 30 at the Birmingham-Jefferson Civic Center (BJCC), where Andrew Yan, founder and CEO of Venture for America, will be the guest speaker.
Trideum Biosciences, a HudsonAlpha associate company, shared the results of their antimicrobial efficacy testing of ChiScan Cold Plasma technology. “Our laboratory has been conducting efficacy testing of this novel next-generation cold plasma technology and I am pleased to announce our testing results demonstrated effectiveness against all the bacterial and fungal pathogens tested” said Dr. Mina Izadjoo, VP and Chief Science Officer of Trideum Biosciences. She also added “We have selected Dr. Hosan Kim, who has extensive experience in antimicrobial efficacy evaluation, to conduct the ongoing testing. The results of antimicrobial testing have been presented in a number of scientific conferences and will be published in peer reviewed journals. This revolutionary cold plasma technology is a promising antibacterial and antifungal medical device for treating localized bacterial and dermatophytic infections and can be used as a countermeasure for multidrug-resistant and hard-to-treat infectious agents.”
Huan Trung, President and CEO of ChiScan LLC, said “We are thrilled to learn of the superior antimicrobial efficacy of our device which is the result of more than 10 years of Research and Development by our team of talented engineers. Our technology will revolutionize the cold plasma field.” He added, “Although currently there a number of technologies capable of generating cold plasma, our proprietary cold plasma generating technology is novel due to its size, being portable with no requirement for any noble gas, its precision, robustness, and ease of application.”
“Trideum Biosciences is committed to providing solutions for hard-to-treat human diseases and we are thrilled to be part of this revolutionary technology,” said Favio Lopez, VP and Chief Operations Officer. Van Sullivan, President and CEO of Trideum Biosciences, said “We are very pleased to have entered into a collaborative partnership with ChiScan and looking forward to many years of a productive collaboration”.
Diatherix to provide laboratory services for the veterans choice program
HudsonAlpha associate company Diatherix Laboratories, LLC, a leading provider of multiplex diagnostic services and solutions, has become a designated provider of laboratory services for the Department of Veterans Affairs (VA) Veterans Choice Program (VCP) alongside TriWest Healthcare Alliance.
As a participant in the VCP, Diatherix administers a comprehensive suite of laboratory benefit management services designed to ensure physicians and VCP members have access to high quality, specialized laboratory testing services for infectious diseases.